ABSTRACT
A high dietary intake of phosphorus is considered to be a significant health threat for hemodialysis (HD) patients. Prescription medications, which might be a major source of phosphorus, is largely unrecognized in Japan. However, the amount of phosphorus indicated on the package label, is not quantified. In this study, the phosphorus content of 22 of the most widely prescribed medications that are used in conjunction with HD therapy were examined and differences between branded and generic prescription medications were compared. All samples were selected from medications that are typically prescribed for HD patients. The samples were ground prior to analysis. Phosphorus was measured using the Wako L-Type Phosphate method. All instruments used in the study were calibrated according to the manufacturers' specifications. Amlodipine (15 mg/tablet) and paroxetine (30.0 mg/tablet) were found to contain higher contents of phosphorus than the medications tested. Differences in phosphorus content between branded and generic drugs was also determined. The phosphorus content of all generic paroxetine preparations was significantly lower than the values for identical branded medications. On the other hand, the phosphorus content of several generic amlodipine preparations were significantly different from those of similar, branded preparations. Specific information regarding the phosphorus content of prescribed medications used by HD patient needs to be made available to the dialysis community.
Subject(s)
Phosphorus/adverse effects , Phosphorus/analysis , Prescription Drugs/chemistry , Renal Dialysis , Amlodipine/chemistry , Drugs, Generic/chemistry , Humans , Japan , Paroxetine/chemistry , Phosphorus, Dietary/adverse effects , Phosphorus, Dietary/analysisABSTRACT
Silibinin is the main constituent of silymarin, an extract from the seeds of milk thistle (Silybum marianum). Because silibinin has many pharmacological activities, extending its clinical use in the treatment of a wider variety of diseases would be desirable. In this study, we report on the binding of silibinin to plasma proteins, an issue that has not previously been extensively studied. The findings indicated that silibinin mainly binds to human serum albumin (HSA). Mutual displacement experiments using ligands that primarily bind to sites I and II clearly revealed that silibinin binds tightly and selectively to site I (subsites Ia and/or Ic) of HSA, which is located in subdomain IIA. Thermodynamic analyses suggested that hydrogen bonding and van der Waals interactions are major contributors to silibinin-HSA interactions. Furthermore, the binding of silibinin to HSA was found to be decreased with increasing ionic strength and detergent concentration of the media, suggesting that electrostatic and hydrophobic interactions are involved in the binding. Trp214 and Arg218 were identified as being involved in the binding of silibinin to site I, based on binding experiments using chemically modified- and mutant-HSAs. In conclusion, the available evidence indicates that silibinin binds to the region close to Trp214 and Arg218 in site I of HSA with assistance by multiple forces and can displace site I drugs (e.g., warfarin or iodipamide), but not site II drugs (e.g., ibuprofen).
Subject(s)
Binding Sites , Serum Albumin/chemistry , Silymarin/chemistry , Herb-Drug Interactions , Humans , Hydrogen Bonding , Hydrophobic and Hydrophilic Interactions , Protein Binding , Seeds , Silybin , Silymarin/pharmacokinetics , Static Electricity , ThermodynamicsABSTRACT
A ferric citrate formulation for treating hyperphosphatemia is a new therapeutic that not only suppresses the accumulation of phosphorus in patients with chronic kidney disease-mineral bone disorders (CKD-MBD), but also ameliorates anemia caused by iron deficiency. In contrast, it has been demonstrated that intravenous iron injection markedly increases oxidative stress. This study was designed to investigate the effect of a ferric citrate formulation on oxidative stress in CKD-MBD patients receiving hemodialysis therapy. Fifteen CKD-MBD patients undergoing dialysis were enrolled in this study. The patients were orally administered a ferric citrate formulation for 6 months. Their plasma phosphorus concentrations remained unchanged with the switch from other phosphorus adsorbents to the ferric citrate formulation. In addition, the ferric citrate formulation generally allowed for dose reduction of an erythropoiesis stimulating agent with an increased hematopoietic effect. The average values of plasma ferritin level increased after the introduction of a ferric citrate formulation, but did not exceed 100 (ng/mL). Interestingly, oxidative stress markers did not increase significantly, and anti-oxidative capacity was not significantly decreased at 6 months after the drug administration. Similarly, no change was observed in any inflammation markers. The ferric citrate formulation induces negligible oxidative stress in CKD-MBD patients receiving dialysis under the present clinical condition.
Subject(s)
Chronic Kidney Disease-Mineral and Bone Disorder/blood , Ferric Compounds/pharmacology , Oxidative Stress/drug effects , Administration, Oral , Aged , Aged, 80 and over , Chronic Kidney Disease-Mineral and Bone Disorder/drug therapy , Female , Ferric Compounds/therapeutic use , Ferritins/blood , Humans , Male , Middle Aged , Phosphates/blood , Phosphorus/blood , Renal DialysisABSTRACT
In recent world-wide studies, chitosans were tested as a dietary supplement for inhibiting the absorption of certain lipids and bile acids. We previously demonstrated the antioxidative and renoprotective potential of chitosan supplementation in chronic renal failure using 5/6 nephrectomized rats. In this study, we report the effects of chitosan on oxidative stress and related factors in hemodialysis patients. The ingestion of chitosan over a 12-week period resulted in a significant decrease in serum indoxyl sulfate and phosphate levels, compared with the levels prior to the start of the study. The ingestion of chitosan also resulted in a lowered ratio of oxidized to reduced albumin and a decrease in the level of advanced oxidized protein products. In in vitro studies, chitosan solutions were found to bind 38.5% of the indoxyl sulfate and 17.8% of the phosphate, respectively. Further, the oxidized albumin ratio was correlated with serum indoxyl sulfate levels in vivo. These results suggest that the ingestion of chitosan results in a significant reduction in the levels of pro-oxidants, which include uremic toxins, in the gastrointestinal tract, thereby inhibiting the subsequent development of oxidative stress in the systemic circulation. In addition, the long-term ingestion of chitosan has the potential for use in treating hyperphosphatemia in hemodialysis patients.
Subject(s)
Chitosan/pharmacology , Oxidative Stress/drug effects , Renal Dialysis/adverse effects , Aged , Antioxidants/metabolism , Antioxidants/pharmacology , Chitosan/metabolism , Humans , Hyperphosphatemia/drug therapy , Indican/blood , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/therapy , Middle Aged , Phosphates/metabolism , Serum Albumin/metabolism , Treatment OutcomeABSTRACT
The degree of oxidized cysteine (Cys) 34 in human serum albumin (HSA), as determined by high performance liquid chromatography (HPLC), is correlated with oxidative stress related pathological conditions. In order to further characterize the oxidation of Cys34-HSA at the molecular level and to develop a suitable analytical method for a rapid and sensitive clinical laboratory analysis, the use of electrospray ionization time-of-flight mass spectrometer (ESI-TOFMS) was evaluated. A marked increase in the cysteinylation of Cys34 occurs in chronic liver and kidney diseases and diabetes mellitus. A significant positive correlation was observed between the Cys-Cys34-HSA fraction of plasma samples obtained from 229 patients, as determined by ESI-TOFMS, and the degree of oxidized Cys34-HSA determined by HPLC. The Cys-Cys34-HSA fraction was significantly increased with the progression of liver cirrhosis, and was reduced by branched chain amino acids (BCAA) treatment. The changes in the Cys-Cys34-HSA fraction were significantly correlated with the alternations of the plasma levels of advanced oxidized protein products, an oxidative stress marker for proteins. The binding ability of endogenous substances (bilirubin and tryptophan) and drugs (warfarin and diazepam) to HSA purified from chronic liver disease patients were significantly suppressed but significantly improved by BCAA supplementation. Interestingly, the changes in this physiological function of HSA in chronic liver disease were correlated with the Cys-Cys34-HSA fraction. In conclusion, ESI-TOFMS is a suitable high throughput method for the rapid and sensitive quantification of Cys-Cys34-HSA in a large number of samples for evaluating oxidative stress related chronic disease progression or in response to a treatment.
Subject(s)
Cysteine/metabolism , Diabetes Mellitus/blood , Liver Cirrhosis/blood , Renal Insufficiency/blood , Serum Albumin/metabolism , Aged , Amino Acids, Branched-Chain/administration & dosage , Bilirubin/chemistry , Biomarkers/blood , Chronic Disease , Cysteine/chemistry , Diabetes Mellitus/diagnosis , Diabetes Mellitus/drug therapy , Diazepam/chemistry , Female , Glycation End Products, Advanced/blood , Humans , Liver Cirrhosis/diagnosis , Liver Cirrhosis/diet therapy , Male , Middle Aged , Models, Molecular , Oxidation-Reduction , Oxidative Stress , Protein Binding , Renal Insufficiency/diagnosis , Renal Insufficiency/diet therapy , Serum Albumin/chemistry , Spectrometry, Mass, Electrospray Ionization , Tryptophan/chemistry , Warfarin/chemistryABSTRACT
In recent years, self-medication is promoted to control the health care cost of aged people in Japan. On the other hand, there are many pharmacists who are perplexed in diversification of work with promotion of self-medication because of shortage of information, including the knowledge of an over-the-counter drug, health food, etc. It is therefore needed to design an efficient education program for pharmacists, especially in aging society such as Fukuyama. In this study, we investigated the needs for self-medication of local residents and community pharmacists in order to clarify the high-priority education themes for promotion of self-medication in Fukuyama. The pharmacist's needs were extracted by the KJ method and prioritized by the two-dimensional developed leaf method, and the local resident's needs were extracted by questionnaire survey from 420 general populations who live in Fukuyama. As a result, we found that the community pharmacists were especially in need of acquisition of the knowledge about "health food" and "food", and the local residents were especially in need of consultation with community pharmacists about "medicine", "side effect of medicine", "health food" and "food". Moreover, we also found that sixty percent of local residents did not have knowledge about interaction of "medicine" and "health food" while the half of them was taking in "health food". From the above result, knowledge improvement of "health food", "food" and "interaction of medicine and health food" in addition to "medicine" and "side effect of medicine" is the high-priority education themes for local residents and community pharmacists to promote self-medication in Fukuyama.
Subject(s)
Community Pharmacy Services , Dietary Supplements , Food, Organic , Needs Assessment , Nonprescription Drugs , Pharmacists , Professional Role , Self Medication , Adult , Aged , Aged, 80 and over , Dietary Supplements/adverse effects , Education, Pharmacy, Continuing , Female , Food, Organic/adverse effects , Health Care Costs , Health Education , Humans , Japan , Knowledge , Male , Middle Aged , Nonprescription Drugs/adverse effectsABSTRACT
The effect of high and low molecular weight chitosans (HMC; 1000 kDa, LMC; 30 kDa) on oxidative stress and hypercholesterolemia was investigated using male 6-week-old Wistar Kyoto rats as a normal model (Normal-rats) and spontaneously hypertensive rat/ND mcr-cp (SHP/ND) as a metabolic syndrome model (MS-rats), respectively. In Normal-rats, the ingestion of both chitosans over a 4 week period resulted in a significant decrease in total body weight (BW), glucose (Gl), triglyceride (TG), low density lipoprotein (LDL) and serum creatinine (Cre) levels. The ingestion of both chitosans also resulted in a lowered ratio of oxidized to reduced albumin and an increase in total plasma antioxidant activity. In addition to similar results in Normal-rats, the ingestion of only HMC over a 4 week period resulted in a significant decrease in total cholesterol levels in MS-rats. Further, the ingestion of LMC resulted in a significantly higher antioxidant activity than was observed for HMC in both rat models. In in vitro studies, LMC caused a significantly higher reduction in the levels of two stable radicals, compared to HMC, and the effect was both dose- and time-dependent. The findings also show that LDL showed strong binding in the case of HMC. These results suggest that LMC has a high antioxidant activity as well as antilipidemic effects, while HMC results in a significant reduction in the levels of pro-oxidants such as LDL in the gastrointestinal tract, thereby inhibiting the subsequent development of oxidative stress in the systemic circulation in metabolic model rats.
Subject(s)
Antioxidants/therapeutic use , Blood Glucose/metabolism , Chitosan/therapeutic use , Cholesterol, LDL/metabolism , Cholesterol/blood , Hypolipidemic Agents/therapeutic use , Metabolic Syndrome/drug therapy , Albumins/metabolism , Animals , Antioxidants/metabolism , Antioxidants/pharmacology , Body Weight/drug effects , Chitosan/pharmacology , Cholesterol/metabolism , Creatinine/blood , Dietary Supplements , Disease Models, Animal , Dose-Response Relationship, Drug , Free Radicals/metabolism , Gastrointestinal Tract/metabolism , Hypolipidemic Agents/pharmacology , Male , Metabolic Syndrome/metabolism , Molecular Weight , Oxidative Stress/drug effects , Rats , Rats, Inbred SHR , Rats, Inbred WKY , Reactive Oxygen Species/blood , Reactive Oxygen Species/metabolism , Reference Values , Triglycerides/bloodABSTRACT
The effect of water-soluble chitosan, a natural polymer derived from chitin, on indices of oxidative stress was investigated in normal volunteers. Treatment with chitosan for 4 weeks produced a significant decrease in levels of plasma glucose, atherogenic index and led to increase in high density lipoprotein cholesterol (HDL). Chitosan treatment also lowered the ratio of oxidized to reduced albumin and increased total plasma antioxidant activity (TPA). There was good correlation between TPA and oxidized albumin ratio. The results indicate that oxidized albumin ratio represents a potentially useful marker of oxidative stress. In in vitro studies, albumin carbonyls and hydroperoxides were significantly decreased in a time-dependent manner in the presence of chitosan, compared with controls (p<0.05). Chitosan also reduced two stable radicals in a dose- and time-dependent manner. The results suggest that chitosan has a direct antioxidant activity in systemic circulation by lowering the indices of oxidative stress in both in vitro and in vivo studies. This may confer benefits additional to the reduction in plasma carbohydrate and increase in HDL levels. It may also inhibit oxidation of serum albumin commonly observed in patients undergoing hemodialysis, resulting in reduction of oxidative stress associated with uremia.